The Angiotensin Converting Enzyme (ACE) Inhibitor SwitchBack Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-07-31

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ACE inhibitors have been studied extensively in the treatment of heart failure and have been shown to be beneficial in all its stages. Studies with the use of angiotensin receptor blockers (ARBs) in chronic heart failure have not shown equivalent results. Many patients are on an ARB for a variety of reasons. Some of these may have had cough as a symptom of heart failure and not due to medication side effect. According to guidelines, angiotensin converting enzyme inhibitors (ACEi) are still first-line therapy in the treatment of heart failure. As ACEi have been extensively studied showing improvement in morbidity and mortality all patients should be on this treatment unless absolutely contraindicated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ACEi ARB Withdrawal in CKD Patients

NCT03957161

Chronic Kidney Disease Blood Pressure Angiotensin-converting Enzyme Inhibitor +1 more

WITHDRAWN NA

The Role of Angiotensin Type I Receptor in the Regulation of Human Peripheral Vascular Function

NCT00001628

Atherosclerosis Heart Failure, Congestive Hypertension +1 more

COMPLETED PHASE3

Empagliflozin in Acute Heart Failure

NCT05305495

Acute Heart Failure Chronic Kidney Diseases

RECRUITING PHASE4

Single and Twice-daily Dosing of Ramipril on Renal Function in Chronic Kidney Disease Patients With Reduced Ejection Fraction Heart Failure

NCT07259512

Chronic Kidney Disease Heart Failure With Reduced Ejection Fraction (HFrEF)

RECRUITING PHASE4

The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function

NCT00001629

Atherosclerosis Heart Failure, Congestive Hypertension +1 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* heart failure patients who have indications for ACEi but are currently on ARBs with no absolute contraindications to ACEi
* patients with an ejection fraction of \< or = 35% verified in the last 12 months by echo, angio, or nuc med who are NYHA class I to IV and followed in a heart failure clinic for three months
* on beta-blockers, unless contra-indicated
* stable on current meds for 3 months (except dose of diuretics)
* able to give informed consent

Exclusion Criteria

* documented angioedema/anaphylaxis with prior ACEi use
* documented worsening renal failure, hyperkalemia, cough and gastrointestinal symptoms that are definitely believed to be due to ACEi
* potassium \>5.0 mmol/L

Eligible Sex

ALL

Accepts Healthy Volunteers

No